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INTRODUCTION
World statistics showed that by the end of 2016, the 
number of people with diabetes is about 420 million 
people. According to the forecast deputy International 
Diabetes Federation, by 2040 the number will increase 
to 642 million people. Considering this development 
of effective medicines for the treatment of diabetes 
is one of the urgent problems of modern medicine. 
Search for innovative molecules[1,2] is an important task 
of pharmacology. In this case, their research should 
contain specific pharmacological activity,[3-7] including 
in vivo[8-12] and in vitro[13] studies, toxicological,[14] 
clinical, and pharmacokinetic studies.[15]
One of the new developments in the treatment 
of diabetes is 3-(1H-benzimidazol-2-yl)-1,2,2-
trimethylcyclopentanecarboxylic acid (C7070) [10] The 
structural formula is shown in Figure 1. Previously, 
we conducted pharmacokinetic studies in rats and 
rabbits.[16]
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Interest in this substance-a potential hypoglycemic 
drug for the treatment of diabetes is due to the fact that 
agonists of imidazoline receptors are antihypertensive 
drugs clonidine, moxonidine, and rilmenidine, as well 
as antidiabetic drug metformin. Anti-hypertensive 
drugs of clonidine, moxonidine, and rilmenidine 
in contrast to 3-(1H-benzimidazol-2-yl)-1,2,2-
trimethylcyclopentanecarboxylic acid do not affect 
glycemic control. The antidiabetic drug metformin 
for safety (acute toxicity, lactic acidosis, and other 
side effects), the breadth of the therapeutic index and 
the severity of antidiabetic properties are inferior to 
C7070. Unlike C7070, metformin has not been proven: 
The ability to restore the physiological function of the 
pancreatic β-cells, cerebroprotective, and nootropic 
effects.
MATERIALS AND METHODS
The object of the current study was pharmaceutical 
substance C7070. Twelve rats (males weighing 350 ± 
20% g) were included in the study. Adaptation time 
before the study was 8 days. In the study, animals were 
selected with no signs of abnormal appearance. The 
basic rules of maintenance and care are in accordance 
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with the regulations given in the Manual Guide for 
the care and use of laboratory animals. The National 
Academies Press. – Washington, D. C. 2011.[17]
The following reagents were used in the work: 
Substance C7070 (CJSC VladMiVa, RF, Belgorod), 
fabomotizole (Sigma), formic acid (PanReac), 
ammonium acetate (PanReac), methanol (Merck), 
acetonitrile for gradient chromatography (Merck), and 
water 18.2 MΩ × cm, obtained with the Gene Pure 
system (Thermo Scientific, USA).
To perform organ distribution studies, tandem mass 
spectrometry (MS/MS) high-performance liquid 
chromatography (HPLC) was developed to determine 
C7070 in rat blood plasma, organ homogenates and 
had full validation.[18] The methods corresponded to the 
requirements of Buzov et al.[19] Guidance for Industry: 
Bioanalytical Method Validation,[20] Mironov et al.[21]
The determination of C7070 in blood plasma, organ 
homogenates of rats was carried out on a liquid 
chromatograph UltiMate 3000 LC (Thermo Fisher 
Scientific, USA) equipped with a thermostable 
automatic dispenser, vacuum degasser, gradient pump, 
and column thermostat. The analyte was detected on a 
Velos Pro Mass Spectrometer (Thermo Scientific, USA) 
with ionization in a heated electrospray (H-ESI-II). 
This equipment has already been used by us earlier[22] 
in quantitative studies and has shown good results.
Sample Preparation
The preparation of the initial solutions of C7070 
included several steps. In the first stage, a stock 
solution of C7070 in methanol with a concentration 
of 0.2% was prepared. In the second stage, C7070 
solutions in methanol were prepared by dilution series 
to be added to standard solutions and quality control 
(QC) solutions with a concentration of 0.00002%, 
0.002%, and 0.011%.
A solution of the internal standard was used at the 
same level of concentrations -0.1% in methanol.
Calibration solutions were prepared at seven 
concentration levels. Intact specimens of organs and 
tissues were used for the preparation of calibration 
solutions. 100 μl of intact final homogenate was 
placed in 1.5 ml Eppendorf tubes, aliquots of the 
starting solutions and 100 μl of the internal standard 
solution was added, mixed, 0.1 ml of acetonitrile 
added, and mixed extracted C7070 in ultrasound for 
20 min. After the sample was frozen at a temperature 
of −70°C. After thawing, it was centrifuged at 13,000 
rpm and 4°C for 25 min. Thus, 14 solutions were 
prepared with seven levels of concentrations: 0.02 μg 
0.19 μg, 1.94 μg, 19.38 μg, 193.80 μg, 1938.00 μg, and 
3876.00 μg in 1 ml plasma. Each level was prepared 
and analyzed twice.
QC solutions were prepared similarly to calibration 
solutions at two concentration levels in two replicates. 
Thus, four solutions were prepared with two levels of 
concentrations −0.19 μg lower QC and 1938.00 upper 
QC in 1 ml of plasma.
Test Solution
A sample of tissue or organ was weighed, mixed in a 
container. An aliquot of water was added to the sample 
in an amount equivalent to the weight of the sample 
and homogenized. Next, the detectable substance was 
extracted from the organ tissues into the liquid phase 
of the homogenate by sonication for 20 min (final 
homogenate).
100 μl of the final homogenate was transferred to an 
Eppendorf tube of 1.5 ml capacity, 100 µl of internal 
solution was added, mixed, 0.1 ml of acetonitrile 
added, and mixed. The extraction of the analyte was 
performed on ultrasound for 20 min. The samples 
were frozen at a temperature of −70°C. After thawing, 
the samples were centrifuged at 13,000 rpm and 4°C 
for 15 min. The supernatant was analyzed.
Study Protocol
Organ distribution was studied after multiple 
intragastric (I.O) administration of C7070 to animals 
at doses of 25 mg/kg and 50 mg/kg. Whole blood, 
plasma, thymus, liver, brain, kidneys, heart, lungs, 
blood, intestines, spleen, skin, muscles, and fat tissue 
were collected.
Parameters HPLC-MS/MS
Chromatographic separation was carried out on a 
150 mm × 3.0 mm column of Zorbax Eclipse XDB 
C18 (Agilent technologies, USA) with a particle size 
of 3.0 μm with a Zorbax Eclipse XDB C18 (Agilent 
technologies, USA) protection column of 12.5 mm × 
3.0 mm with a particle size of 5.0 μm, at a temperature 
Figure 1: Structural formula C7070
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Table 1: Parameters of the chromatographic system
UltiMate 3000 LC
Sample volume (μl) 2
Mobile phase
Gradient according to the following program
Time, min Flow, ml/min 5 mM ammonium 
acetate+0.1% formic acid
Acetonitrile, % Methanol, %
0 0.4 80 20 0
5.0 0.4 80 20 0
8.5 0.4 75 10 15
9.0 0.4 20 70 10
11.0 0.4 20 70 10
11.1 0.4 80 20 0
12.5 0.4 80 20 0
Retention times (min) C7070 - about 4.7; The internal standard - about 8.5
Injection time (min) 12.5
Velos Pro
Tool Velos Pro (Thermo Scientific, США)
Ionization type H-ESI
Polarity С7070 “+”; Internal standard “+”
Mass transfer С7070–272.35→255.15;  Internal standard–307.41→114
Collision energy С7070–42;  Internal standard–19
Voltage at source (V) С7070–3000;  Internal standard–3000
Source temperature (°C) С7070–300; Internal standard–300
Capillary temperature (°C) С7070–350; Internal standard–350
Sheath gas pressure (Arb) С7070–60; Internal standard–60
Aux gas pressure (Arb) С7070–20; Internal standard–20
Figure 2: The distribution diagram of C7070 in organs at a dose of 25 mg/kg
Figure 3: The distribution diagram of C7070 in organs at a dose of 50 mg/kg
Alexander L. Kulikov, et al.
3361Drug Invention Today | Vol 11 • Issue 12 • 2019
of 40°C. The parameters of the chromatographic 
system are presented in Table 1.
RESULTS
The main distribution parameters were calculated 
on the basis of experimental results. Concentrations 
of C7070 in the investigated objects were calculated 
from calibration curves. The sharply highlighted 
results (outliers) in animals at each time point were 
detected using the Grubbs statistical criterion.[23]
The distribution of C7070 in organs is shown in 
Figures 2 and 3.
The drug is well distributed into organs. The greatest 
content of C7070 was observed in the tissues of the 
small intestine. The smallest content of C7070 was 
observed in muscle tissue and brain.
Calculation of the apparent distribution coefficient 
(Kd) C70707 between plasma and tissues in rabbits 
with I.O. administration is presented in Table 2.
The present data show that C7070 intensively 
penetrates into organs and tissues with a high level 
of hemocirculation. The greatest content of C7070 
is characteristic of the small intestine, kidneys, skin, 
liver, and adipose tissue. The distribution of the drug 
in the lungs, heart, and spleen is close. A similar 
maximum concentration is characteristic of these 
organs. The smallest distribution of the drug C7070 is 
fixed for muscles and brain.
CONCLUSION
In the course of the work, it was established that the 
investigated drug substance C7070 is well absorbed 
from the gastrointestinal tract and distributed along 
with the tissues. The highest content is observed 
in the small intestine, probably here is the systemic 
absorption. The experimental data of Kd show that 
the preparation intensively penetrates into the tissue 
(min = 3.7 ± 4.0, max = 537.8 ± 95.9). This indicator 
is of primary importance for hypoglycemic agents. 
The parameters obtained can be useful for clinical 
application and further studies of preparations C7070 
on its basis.[24-27]
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